Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Immune Globulin Intravenous (Human), 10% Solution
Takeda
Primary Immunodeficiency Diseases (PID)
1 trial -
Immune Globulin Intravenous (IGIV)
Takeda
Primary Immunodeficiency Diseases (PID)
1 trial -
Immune Globulin Subcutaneous (Human), 20%
Takeda
Primary Immunodeficiency Diseases (PID)
1 trial -
Immunonutrition (Su yusu)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastrointestinal Tumors
1 trial -
Imnovid 1 mg hard capsules, CC-92480, CC-92480, Dexamethason-ratiopharm® 4 mg Tabletten, Imnovid 4 mg hard capsules, Dexamethason CF 20 mg/ml, injectievloeistof, CC-92480, Dexamethason 4 mg JENAPHARM®, Imnovid 2 mg hard capsules, DEXAMETHASONE, Dexamethason 4 mg GALEN®, CC-92480, Imnovid 3 mg hard capsules, CC-92480, CC-92480, VELCADE 1 mg powder for solution for injection
Celgene Europe Limited
Relapsed or Refractory Multiple Myeloma (RRMM)
1 trial -
Imnovid 1 mg hard capsules, Kyprolis 60 mg powder for solution for infusion, Privigen 100 mg/ml solution for infusion, Pomalidomide, Pomalidomide, Dexamethason 8 mg GALEN® Tabletten, VELCADE 3.5 mg powder for solution for injection, Imnovid 3 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Privigen 100 mg/ml solution for infusion, teclistamab, Pomalidomide, Dexamethason 4 mg JENAPHARM®, Fortecortin® 2 mg Tabletten, teclistamab, Pomalidomide, Imnovid 4 mg hard capsules, Privigen 100 mg/ml solution for infu
Janssen-Cilag International N.V.
Relapsed/refractory multiple myeloma
1 trial -
Imnovid 3 mg hard capsules, DARZALEX 20 mg/mL concentrate for solution for infusion, Bortezomib Fresenius Kabi 3.5 mg powder for solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, Kyprolis 30 mg powder for solution for infusion, Kyprolis 60 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Neofordex 40 mg tablets, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules, Kyprolis 10 mg powder for solution for infusion, Anitocabtagene autoleucel, Bortezomib Freseniu
Lacuna Pharma Pty Ltd
Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody
1 trial -
Imnovid 3 mg hard capsules, DEXAMETHASONE , Venetoclax, Imnovid 1 mg hard capsules, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules
AbbVie Deutschland GmbH & Co. KG
R/R Multiple Myeloma
1 trial -
Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Dexamethason 8 mg GALEN® Tabletten, Imnovid 2 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Dexamethasone 2mg Tablets, Imnovid 1 mg hard capsules, VELCADE 3.5 mg powder for solution for injection
GlaxoSmithKline
Relapsed/Refractory Multiple Myeloma
1 trial -
Imnovid 3 mg hard capsules, Isatuximab, Dexamethason 4 mg JENAPHARM®, JAMP Pomalidomide, JAMP Pomalidomide, Isatuximab, Imnovid 4 mg hard capsules, JAMP Pomalidomide, MONTELUKAST , Pomalidomide Adalvo 4 mg hard capsules, JAMP Pomalidomide, Imnovid 2 mg hard capsules, Pomalidomide Adalvo 2 mg hard capsules, Imnovid 1 mg hard capsules, Pomalidomide Adalvo 3 mg hard capsules, DEXAMETHASONE, Imnovid 1 mg hard capsules, Isatuximab, Imnovid 2 mg hard capsules, Pomalidomide Adalvo 1 mg hard capsules, Dexamethason
Sanofi-aventis Healthcare Pty Ltd
Cancer - Plasma cell myeloma recurrent
1 trial -
Inactivated COVID-19 Vaccine
Sinovac Research and Development Co.,
COVID-19
4 trials -
Inactivated Poliomyelitis Vaccine (Sabin strains)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Poliomyelitis
2 trials -
Individualized Elective Neck Irradiation
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Sinovac Research and Development Co.,
Seasonal Influenza
1 trial -
Influenza vaccine
Lxo Ireland Designated Activity Company
Infection in Solid Organ Transplant Recipients
1 trial -
Influsplit Tetra 2024/2025 Injektionssuspension in Fertigspritze Influenza-Spaltimpfstoff (inaktiviert)
Moderna Biotech Spain
Influenza
1 trial -
Insulatard 100 international units/ml suspension for injection in vial., Natriumchloride 0,9% oplossing voor injectie
Disc Medicine
Delirium
1 trial -
Insulin Degludec and Insulin Aspart
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Diabetes
1 trial -
Insulin degludec/insulin aspart
Novo Nordisk A/S
Diabetes
1 trial -
Insulin glargine/Lixisenatide (HOE901/AVE0010)
Sanofi Pasteur
Type 2 Diabetes Mellitus
1 trial -
Insulin icodec
Novo Nordisk A/S
Diabetes, Type 2
1 trial -
Internet-based smoking treatment
BRIGHT MINDS BIOSCIENCES INC.
Nicotine Dependence
1 trial -
Intervention
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HIV
1 trial -
Intra-arterial thrombolysis
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Ischemic Stroke
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources